Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema

PHASE3CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 15, 2021

Study Completion Date

February 15, 2021

Conditions
Inflammatory Macular Edema
Interventions
DRUG

Dexamethasone

Intravitreal implant at D0

DRUG

Triamcinolone

Subconjunctival injection at 4 mm from the limbus at 6 o'clock

Trial Locations (16)

21079

CHU de Dijon, Dijon

29609

CHU de Brest, Brest

33076

CHU de Bordeaux, Bordeaux

34295

CHU de Montpellier, Montpellier

37044

CHU de Tours, Tours

38700

CHU de Grenoble, La Tronche

44093

CHU de Nantes, Nantes

54500

CHU de Nancy, Vandœuvre-lès-Nancy

59037

CHRU de Lille, Lille

69004

Hopices Civils de Lyon, Lyon

75013

Hôpital La Pitié-Salpêtrière (AP-HP), Paris

75019

Fondation Ophtalmologique Adolphe de Rothschild, Paris

75571

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris

94270

Hôpital Bicêtre (AP-HP), Le Kremlin-Bicêtre

Unknown

CHU Angers, Angers

06000

CHU de Nice, Nice

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT02556424 - Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema | Biotech Hunter | Biotech Hunter